FabriceAndre

Wow! Not 1️⃣, not 2️⃣, but 3️⃣‼️@Nature papers concomitantly published during #ESMO25 @myESMO @LoiSher @adam_grippin @MDAndersonNews @PeterMacCC @NKI_nl @DrChoueiri @VanAllenLab @FAndreMD congrats to all authors and 🙏 for making this very unique session happen also @Nature ! 👇

📣 ESMOImmuno25: Aurélien Marabelle, Scientific Co-Chair, invites you to present your research to an international audience of top-tier scientists, clinicians, and industry experts. ⏰ Deadline: 30 September 2025 🔗 ow.ly/PXBG50WnEQ4

📣 Join us in Hong Kong for a chance to contribute to oncology drug development in Asia Pacific! ⏰ Late registration deadline: 18 June 🔗 ow.ly/MWyG50W90Ef @herbloong @TonyMok9 @DrBenTran @AyaHelali

At #ASCO25, the Joint Session between ASCO and @myESMO will discuss emerging trends & the implications of integrating biomarker testing into clinical care. #ASCODailyNews has more on this with: @ASCOPres @BenWestphalen @FAndreMD @DrBonillaOnc @jrgralow: brnw.ch/21wSLDe

#ESMOBreast25 is next month. Love this "digestible" breast only meeting with the benefits of extra interaction with all of our international colleagues. Registration: esmo.org/meeting-calend… Program: cslide.ctimeetingtech.com/coasis_21219/a… #bcsm @myESMO @curijoey @FAndreMD

📢 #ESMOFellowship applications are now open! The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch or #ClinicalResearch projects. 📅 Apply by: 29 May 2025 🔗 ow.ly/tz3e50VAQuM @E_de_Azambuja @TeresaSAmaral

It was very sad to learn that M Schneider passed away. Maurice created @myESMO in 1975 together with G Mathe, in @VilledeNice 50 years later, @myESMO includes almost 45k members around the 🌍, trains all generations of doctors and transforms practice of oncology w its frameworks

📣ESMO #ClinicalPracticeGuideline Express Update on #PancreaticCancer: updated 1st- & #2nd-line treatment recommendations for managing #MetastaticPancreaticCancer, following approval of 1st-line nanoliposomal #irinotecan. #ESMOGuidelines 🔗ow.ly/H7Ap50Vx9Qj

👉 Share your findings with regional and international experts in #cancer #drugdevelopment. ⏰ You still have 3 weeks to submit your abstract to #ESMOTATAsia25, a new platform to improve cancer care in the region Submit now: 🔗 ow.ly/iagq50VuAmn

Abstract submission now open for #ESMO25 in #BERLIN! We have a fantastic educational programme in place, and now it's time for the scientific programme. Looking forward to your abstracts! Deadline: May13th esmo.org/meeting-calend… @DrChoueiri @myESMO @DrChoueiri @FAndreMD

📣 Join us for an insightful ESMO Webinar on Advanced Urothelial Cancer! 👩‍⚕️Our expert panel will discuss 1st & 2nd line therapies, toxicity management & more. Live Q&A included. 👉Register now! #UrothelialCancer 🔗ow.ly/Etpg50V07hR

📣 ESMO #ClinicalPracticeGuideline eUpdate on #OesophagealCancer: in resectable, locally advanced oesophageal adenocarcinoma or OGJ pre- & post-operative #chemotherapy is associated with improved survival vs #Neoadjuvant #Chemoradiotherapy. 🔗 ow.ly/R37w50UYlE9

Opening session of #ESMOAFrica2025 by the @myESMO president @FAndreMD with the amazing audience from all over Africa. @OncoAlert @curijoey @E_de_Azambuja

Get the latest in early clinical trials at ESMO TAT 2025, from bispecific antibodies for IO, cell therapies in solid tumours (CART, NK cells, modified TCRs, TIL therapy) to MAPkinase pathway and associated targets (KRAS G12C, MAP2K4, combos). Register now!

ESMO announces @Philippe_Bedard as the recipient of the 2025 TAT Honorary Award for his outstanding contributions to advancing targeted anticancer therapies. 📅 He will deliver his award lecture on 3 March at the #ESMOTAT25 in Paris 📌 ow.ly/eue550UT7eX

La station de métro Villejuif - Gustave Roussy de la @Ligne14_RATP a ouvert ses portes aujourd'hui ! Plus qu'une #station, c'est un lien direct qui rapproche des milliers de personnes des soins, de l'innovation et de la recherche.

⏰ Final hours to benefit from the best rates for #ESMOTAT25 👉 Be part of this multi-stakeholder forum to discover the future of anticancer drugs. Early registration ends on 15 Jan at 23:59 CET. 🔗 Secure your place here: ow.ly/Kw6i50UGJ41

Don’t miss this one ! 4th “exchanges “ between @DanaFarber & @GustaveRoussy —this time around “Radioligand Therapies”, with the help of @Servier support and @Medscape for logistics--March 25th in beautiful Paris! Free registration: events.medscapelive.org/website/82041/ @OncoAlert @Medscape @DanaFarber_GU @barlesi @FAndreMD @ellenberlin @PrafulRavi1 @HJacene

Here's our latest, led by Drs. Riaz Gillani & @RyanLCollins13 - we studied a type of inherited genetic event (structural variants) + risk of developing certain cancers in kids: @DanaFarberNews @DFCIPopSci @BostonChildrens @broadinstitute @ScienceMagazine science.org/doi/10.1126/sc…

🚨 This is your last chance to register for the 40th edition of the Chemotherapy courses of @GustaveRoussy. 🚨 Join us for the 40th anniversary of this annual event and discuss with us the last updates about #cancer treatment: tinyurl.com/5cfyx7t8